Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Drug Makers Taking Mixed Disclosure Policies for Coronavirus Infections
August 25, 2020
- Takeda to Sell Japan OTC Biz to Blackstone, Weber Says It’s the Right Choice
August 25, 2020
- Takeda to Offload Japan OTC Biz to Blackstone for 242 Billion Yen
August 24, 2020
- Japan Drug Makers’ Q1 Profit Surges on Voluntary Bans on Doctor Calls: Jiho Tally
August 24, 2020
- Japan Approves CureApp’s Smoking Cessation Apps
August 24, 2020
- Long-Term Prescriptions Up for Expectorants, Bronchodilators amid COVID-19 Emergency: Survey
August 24, 2020
- 4 Drug Makers Flag GLP-1 Use for “Weight Loss” after Diabetes Society Warning
August 24, 2020
- BMS Introduces New Corporate Brand in Japan
August 21, 2020
- Viltepso Now Available in US: Nippon Shinyaku
August 21, 2020
- 4 Add’l Products Recalled over Flawed Testing at Kyowa CritiCare
August 20, 2020
- Boehringer’s Ofev Already Hits Japan Peak Sales Outlook, Momentum Likely to Continue with New Indications
August 20, 2020
- Type 2 Diabetes, Essential Hypertension Most Common Comorbidities in Patients Who Died from COVID-19
August 19, 2020
- ASKA to Snap Up 24.9% Stake in Vietnam Drug Maker
August 19, 2020
- US FDA Accepts Myovant’s Relugolix Triple Combo for Review in Uterine Fibroids
August 19, 2020
- Novo to Skip August Listing for 1st Oral GLP Agent Rybelsus
August 18, 2020
- Pfizer Japan Takes Generic Contenders to Court over Lyrica Patent
August 18, 2020
- Takeda to Introduce Early Retirement Program for Japan Staffers
August 18, 2020
- Fujifilm to Make Antigen for Novavax’s COVID-19 Vaccine for UK Govt
August 18, 2020
- Japan Pharma Market Down 2.5% in April-June: IQVIA
August 18, 2020
- Solasia Gets Japan Rights to Isofol’s Cancer Drug
August 17, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…